Treatment News : Approval Application for Gilead’s Novel Booster Cobicistat Filed with FDA

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » June 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

June 28, 2012

Approval Application for Gilead’s Novel Booster Cobicistat Filed with FDA

A day after Gilead Sciences filed a New Drug Application (NDA) for its integrase inhibitor elvitegravir, the company announced on June 28 that it has submitted the necessary paperwork to the U.S. Food and Drug Administration requesting approval for its experimental pharmacoenhancing agent cobicistat (GS-9350).

If found to be safe and effective by the agency, cobicistat may be given marketing clearance to be used in combination with various antiretroviral medications, notably Reyataz (atazanavir) and Prezista (darunavir), as an alternative to low-dose Norvir (ritonavir) to boost their blood levels and allow for simplified dosing.

The company’s “Quad” fixed-dose combination tablet—containing cobicistat, the experimental integrase inhibitor elvitegravir, and the nucleoside reverse transcriptase inhibitors tenofovir and emtricitabine—was recently recommended for approval by the FDA’s Antiviral Drugs Advisory Committee for people living with HIV starting ARV therapy for the first time.

The NDA for cobicistat, supporting its use as a separate drug in combination with approved ARVs, is based on 48-week data from a Phase III study in which the agent was found to be comparable to Norvir when both boosters were administered with a background regimen of Reyataz plus Truvada (emtricitabine plus tenofovir).

The application is also supported by data demonstrating that cobicistat boosts blood levels of atazanavir and darunavir similar to ritonavir.

Gilead entered into an agreement with Janssen Therapeutics in June 2011 for the development of a fixed-dose combination tablet containing cobicistat and Prezista. In October 2011, Gilead announced an agreement with Bristol-Myers Squibb to develop a fixed-dose combination of cobicistat and Reyataz.

Search: cobicistat, gilead, booster, ritonavir, norvir, prezista, reyataz, nda, approval, fda


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         


[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    fokisi
    Long Beach
    California


    zeze42
    Bay Area - Peninsula
    California


    cortaza100
    Oakland
    California

This could be you!
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.